Welcome
Support Centre
21 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
Influence of long term administration of fluoxetine on cerebral threshold and muscle activation patterns in chronic stroke
ISRCTN ISRCTN46063747
ClinicalTrials.gov identifier
Public title Influence of long term administration of fluoxetine on cerebral threshold and muscle activation patterns in chronic stroke
Scientific title
Acronym flu2006
Serial number at source 1
Study hypothesis 1. Long term use of fluoxetine causes the excitability of the primary motor area of the brain to change
2. Long term administration of fluoxetine causes the muscle activation patterns to change
Lay summary
Ethics approval Approval received from the Medical Ethics committee of Medisch Spectrum Twente (Enschede, The Netherlands) on the 7th February 2007 (ref: P06-53).
Study design Randomised, placebo controlled, parallel group, double blinded trial
Countries of recruitment Netherlands
Disease/condition/study domain Stroke
Participants - inclusion criteria 1. Chronic ischaemic stroke patients (more than six months after stroke)
2. Aged over 18
Participants - exclusion criteria 1. Patients suffering from another neurological disease
2. Uncompensated hemineglect or cognitive disabilities
3. Epilepsy, or first epileptic insult post stroke
4. Patients with first grade relatives suffering from epilepsy
5. Pregnancy
6. Pacemaker
7. Pathological heart rhythms disorders
8. Use of anti-depressants
Anticipated start date 01/01/2007
Anticipated end date 31/12/2008
Status of trial Completed
Patient information material
Target number of participants 28
Interventions 20 mg of fluoxetine during 12 weeks versus placebo.
Primary outcome measure(s) 1. Excitability of the primary motor area, measured by motor threshold and stimulus response curve
2. Muscle activation, measured by calculating Root Mean Square (RMS) during isometric and dynamic movements
Secondary outcome measure(s) 1. Brain activation patterns
2. Phase synchronisation of the brain
3. Motor function
Sources of funding 1. St. Jorisstichting (The Netherlands)
2. Ridderlijke Duitsche Order (The Netherlands)
Trial website
Publications
Contact name Dr  H I  van Genderen
  Address Rehabilitation Centre 'The Roessingh' Enschede
P.O. Box 310
  City/town Enschede
  Zip/Postcode 7500 AH
  Country Netherlands
  Tel +31 (0)53 487 5765
  Fax +31 (0)53 434 0849
  Email h.vangenderen@rrd.nl
Sponsor Rehabilitation Centre 'The Roessingh' Enschede (The Netherlands)
  Address P.O. Box 310
  City/town Enschede
  Zip/Postcode 7500 AH
  Country Netherlands
  Email m.j.ijzerman@utwente.nl
  Sponsor website: http://www.rrd.nl/www/indexa.html
Date applied 28/12/2006
Last edited 16/02/2007
Date ISRCTN assigned 28/12/2006
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central